[1] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[2] |
LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan.
Research Progress in Biological Activity and Mechanisms of Pachymic Acid
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
|
[3] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[4] |
CHEN Qi, ZHANG Mingqiang, GUO Jun.
One Case of Interstitial Pneumonia Caused by Imatinib Mesylate Tablets during the Treatment of Gastric Stromal Tumor
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 463-465.
|
[5] |
LI Bo, XU Liu, XIE Yuqing, WANG Yiying, DONG Shuai, LIAN Jie, LI Guodong, CAO Huijuan.
Safety and Efficacy of Chinese Herbal Patent Medicines for COVID-19: an Umbrella Review
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 155-161.
|
[6] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[7] |
WU Yi, HE Jinyang, WANG Xiaojian, ZhOU Xiaozhu, LIU Ranjia, GUO Mingxing, ZHAO Ying, DAI Wendi, CUI Xiangli.
Adverse events of COVID-19 vaccination in recipients of liver and kidney transplant based on US VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 572-579.
|
[8] |
CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin.
One case of interstitial pneumonia caused by serplulimab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
|
[9] |
LIU Sujie, YAN Jiahe, RUAN Jiaxin, WANG Chen, WANG Xiaofan, LIU Shumin, BAI Xue.
Research Progress in Regulation of Wnt/β-Catenin Signaling Pathway by TCM in the Treatment of Ischemic Stroke
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1388-1392.
|
[10] |
BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, TAN Tianyang, LIU Zhenquan.
Research Progress on the Potential Therapeutic Effect of Bushen Shengjing Prescription on Oligoasthenozoospermia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1243-1249.
|
[11] |
LUO Yuchen, GONG Qingmei, XU Yuhang, QIN Shuqin, ZHANG Jian.
One Case of Acute Respiratory Distress Syndrome Caused by Indapamide Tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1312-1314.
|
[12] |
ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan.
Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
|
[13] |
LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan.
Research status of cognitive dysfunction after SARS-CoV-2 infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
|
[14] |
LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli.
Adverse reactions in patients with COVID-19 after using tocilizumab
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
|
[15] |
YANG Qiuyue, SU Jun, ZHANG Xue, XIE Jiangan.
Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1141-1147.
|